{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"MRD negativity by Clonal Sequencing (ClonoSEQTM) assay (Adaptive Biotechnologies)","groups":[{"description":"Revlimid, Velcade, dexamethasone and Farydak","id":"OG000","title":"Arm 1 - RVD + Pan"},{"description":"Revlimid, Velcade and Dexamethasone","id":"OG001","title":"Arm 2 - RVD"}],"populationDescription":"The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.","reportingStatus":"POSTED","timeFrame":"Month 3","title":"Minimal Residual Disease (MRD) Negativity (mCR) After 4 Cycles of Induction by Next Gen Sequencing","type":"SECONDARY"}